FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 Visualizzazioni· 09/21/23
OncLive® On Air
OncLive® On Air
0 Iscritti
0
In

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Mostra di più

 0 Commenti sort   Ordina per


Avanti il prossimo